There has been a worldwide increase in the numbers and complexity of cancer cases, alongside a predicted global shortage of pathologists. With this, classic manual analysis does not have the capability to support the precision medicine and drug development processes of the future.
Through its precision diagnostics platform, Aignostics turns complex biomedical data into transformative insights. It is able to power target identification (for drug development) and biomarker analyses, as well as support clinical trials with its toolkits.
The company is expanding its platform and reach, with initiatives like its Research Access Program driving adoption within the academic community. By offering free access to its spatial analysis tools, Aignostics is strengthening its data assets, validation base, and relationships with key opinion leaders. Alongside its US expansion and collaboration with the Mayo Clinic, these efforts support its long-term growth across research and biopharma applications.
Steph
Company Specialist at Welcome to the Jungle